Transcriptomic Study of Cutaneous Fibroblasts in Scleroderma
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Skin samples, Analysis of fibroblasts.
- Who it may be relevant to
- Registry conditions: Scleroderma. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
Scleroderma is a complex connective tissue disease involving three interconnected pathophysiological axes: vascular hyperactivity and remodelling, immune system dysfunction and over-activation of fibroblasts at the origin of the fibrosis process in the skin and organs. Given that this pathology occurs preferentially in mature subjects, it is possible to suggest a potential inductive role for senescent fibroblasts, which would be responsible for activating and/or maintaining the immune response and systemic inflammation. Our hypothesis is that fibroblasts play a predominant role in the genesis and maintenance of this pathology.
Interventions
- Procedure Skin samples
* Scleroderma group: skin biopsy for scleroderma patients * Control group: recovery of resected tissue from patients undergoing plastic, reconstructive and aesthetic surgery. - Other Analysis of fibroblasts
Analysis of samples by RNA sequencing
Primary outcome measures
- genes involved in the various cell activation and signalling pathways [Time frame: through study completion, an average of 12 months]
Eligibility criteria
Inclusion criteria
FOR PATIENTS WITH SCLERODERMA :
- Person who has given written consent
- Person with systemic scleroderma
FOR CONTROL PARTICIPANTS :
- Person who has given written consent
- Person undergoing plastic, cosmetic and reconstructive surgery
Exclusion criteria
FOR PATIENTS WITH SCLERODERMA :
- Person not affiliated to or not benefiting from a social security scheme
- Person subject to a legal protection measure (curatorship, guardianship)
- Person subject to a legal protection measure
- An adult who is incapable or unable to give consent
- Minors
FOR CONTROLLED PARTICIPANTS :
- Person suffering from a chronic disease or under chronic treatment for autoimmune, inflammatory or dermatological diseases
- Person not affiliated to or not benefiting from a social security scheme
- Person under legal protection (curatorship, guardianship)
- Person subject to a legal protection measure
- An adult who is incapable or unable to give consent
- Minors
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Cohort
Study locations
France · 1 center
- CHU Dijon Bourgogne — Dijon
Identifiers
NCT: NCT07256418 · BONNOTTE 2025-2